Minoru Takata
YOU?
Author Swipe
View article: Recent advances in understanding the molecular mechanisms of SLX4 recruitment in the replication stress response
Recent advances in understanding the molecular mechanisms of SLX4 recruitment in the replication stress response Open
View article: GENETIC LANDSCAPE OF MYELOID NEOPLASMS IN PATIENTS WITH FANCONI ANEMIA
GENETIC LANDSCAPE OF MYELOID NEOPLASMS IN PATIENTS WITH FANCONI ANEMIA Open
Introduction: Fanconi anemia (FA) is an inherited bone marrow failure syndrome characterized with chromosomal instability and a high propensity to myeloid malignancy. Although causative genes have been identified in most patients, the gene…
View article: Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response
Mouse Slfn8 and Slfn9 genes complement human cells lacking SLFN11 during the replication stress response Open
View article: Supplementary Figure 1 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure 1 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 50K, Western blot showing PTEN expression in PC-9, A549, H1299 and PC-3 cells.
View article: Supplementary Figure 2 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure 2 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 49K, Western blot showing Mre11 expression in H1650 and Mre11-transfected H1650 cells.
View article: Supplementary Figure Legend from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure Legend from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 78K
View article: Supplementary Figure 4 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure 4 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 76K, Western blot analysis of cleaved-caspase 3 in H1650, H1650PTEN+, PC-9 and PC-9PTEN- xenografts. The combination of cisplatin with olaparib seemed to have more cleaved-caspase 3 expressions than other treatments in H1650 and…
View article: Supplementary Figure Legend from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure Legend from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 78K
View article: Supplementary Tables 1 - 3 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Tables 1 - 3 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - Combination index (CI) according to various concentration ratios of cisplatin and olaparib in each cell line was described; Drug sensitivity; Concentration ratio (molar) of cisplatin to olaparib.
View article: Supplementary Figure 1 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure 1 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 50K, Western blot showing PTEN expression in PC-9, A549, H1299 and PC-3 cells.
View article: Data from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Data from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PARP enzyme plays a key role in the cellular machinery responsible for DNA damage repair. PTEN is a tumor-suppressor gene deactivating PI3K downstream of EGFR signaling. We hypothesize that PTEN-deficient lung cancer c…
View article: Supplementary Methods from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Methods from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 79K
View article: Supplementary Figure 3 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure 3 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 147K, A: Subcellular localization of RPA and γH2AX in H1650 or H1650PTEN+ cells after exposure of olaparib (20 μM). B: PTEN deficiency resulted in significant reduction in RPA focus formation after exposure of cisplatin (10 μM) …
View article: Supplementary Figure 2 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure 2 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 49K, Western blot showing Mre11 expression in H1650 and Mre11-transfected H1650 cells.
View article: Supplementary Figure 5 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure 5 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 61K, Western blot showing RAD51 and RPA levels in H1650, H1650PTEN+, PC-9 and PC-9PTEN- cells.
View article: Supplementary Figure 4 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure 4 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 76K, Western blot analysis of cleaved-caspase 3 in H1650, H1650PTEN+, PC-9 and PC-9PTEN- xenografts. The combination of cisplatin with olaparib seemed to have more cleaved-caspase 3 expressions than other treatments in H1650 and…
View article: Data from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Data from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PARP enzyme plays a key role in the cellular machinery responsible for DNA damage repair. PTEN is a tumor-suppressor gene deactivating PI3K downstream of EGFR signaling. We hypothesize that PTEN-deficient lung cancer c…
View article: Supplementary Figure 5 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure 5 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 61K, Western blot showing RAD51 and RPA levels in H1650, H1650PTEN+, PC-9 and PC-9PTEN- cells.
View article: Supplementary Figure 3 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Figure 3 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 147K, A: Subcellular localization of RPA and γH2AX in H1650 or H1650PTEN+ cells after exposure of olaparib (20 μM). B: PTEN deficiency resulted in significant reduction in RPA focus formation after exposure of cisplatin (10 μM) …
View article: Supplementary Tables 1 - 3 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Tables 1 - 3 from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - Combination index (CI) according to various concentration ratios of cisplatin and olaparib in each cell line was described; Drug sensitivity; Concentration ratio (molar) of cisplatin to olaparib.
View article: Supplementary Methods from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells
Supplementary Methods from Synergistic Effect of Olaparib with Combination of Cisplatin on <i>PTEN</i>-Deficient Lung Cancer Cells Open
PDF file - 79K
View article: Supplementary Data from Multiple Repair Pathways Mediate Tolerance to Chemotherapeutic Cross-linking Agents in Vertebrate Cells
Supplementary Data from Multiple Repair Pathways Mediate Tolerance to Chemotherapeutic Cross-linking Agents in Vertebrate Cells Open
Supplementary Data from Multiple Repair Pathways Mediate Tolerance to Chemotherapeutic Cross-linking Agents in Vertebrate Cells
View article: Supplementary Figure 7 from ATR–ATRIP Kinase Complex Triggers Activation of the Fanconi Anemia DNA Repair Pathway
Supplementary Figure 7 from ATR–ATRIP Kinase Complex Triggers Activation of the Fanconi Anemia DNA Repair Pathway Open
PDF file - 1.3MB
View article: Data from Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice
Data from Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice Open
Twenty-five percent of all lung cancer cases are not attributable to smoking. Epidermal growth factor receptor (EGFR) mutations, which are involved in ∼50% of nonsmoker lung cancer, are positively correlated with responsiveness to gefitini…
View article: Supplementary Figure 5 from ATR–ATRIP Kinase Complex Triggers Activation of the Fanconi Anemia DNA Repair Pathway
Supplementary Figure 5 from ATR–ATRIP Kinase Complex Triggers Activation of the Fanconi Anemia DNA Repair Pathway Open
PDF file - 1.2MB
View article: Supplementary Figure 4 from ATR–ATRIP Kinase Complex Triggers Activation of the Fanconi Anemia DNA Repair Pathway
Supplementary Figure 4 from ATR–ATRIP Kinase Complex Triggers Activation of the Fanconi Anemia DNA Repair Pathway Open
PDF file - 1MB
View article: Data from Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice
Data from Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice Open
Twenty-five percent of all lung cancer cases are not attributable to smoking. Epidermal growth factor receptor (EGFR) mutations, which are involved in ∼50% of nonsmoker lung cancer, are positively correlated with responsiveness to gefitini…
View article: Supplementary Figure 1 from A New Melanoma Antigen Fatty Acid–Binding Protein 7, Involved in Proliferation and Invasion, Is a Potential Target for Immunotherapy and Molecular Target Therapy
Supplementary Figure 1 from A New Melanoma Antigen Fatty Acid–Binding Protein 7, Involved in Proliferation and Invasion, Is a Potential Target for Immunotherapy and Molecular Target Therapy Open
Supplementary Figure 1 from A New Melanoma Antigen Fatty Acid–Binding Protein 7, Involved in Proliferation and Invasion, Is a Potential Target for Immunotherapy and Molecular Target Therapy
View article: Supplementary Figure 1 from Cells Deficient in the FANC/BRCA Pathway Are Hypersensitive to Plasma Levels of Formaldehyde
Supplementary Figure 1 from Cells Deficient in the FANC/BRCA Pathway Are Hypersensitive to Plasma Levels of Formaldehyde Open
Supplementary Figure 1 from Cells Deficient in the FANC/BRCA Pathway Are Hypersensitive to Plasma Levels of Formaldehyde
View article: Supplementary Figure Legends 1-2 from Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice
Supplementary Figure Legends 1-2 from Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice Open
Supplementary Figure Legends 1-2 from Chemopreventive Effects of Gefitinib on Nonsmoking-Related Lung Tumorigenesis in Activating Epidermal Growth Factor Receptor Transgenic Mice